×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AMRN – amarin corporation plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AMRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/9
04:15 pm
amrn
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Low
Report
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
11/3
08:30 am
amrn
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
Medium
Report
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
11/1
01:04 am
amrn
Amarin (NASDAQ:AMRN) was upgraded by analysts at Wall Street Zen fro
Medium
Report
Amarin (NASDAQ:AMRN) was upgraded by analysts at Wall Street Zen fro
10/29
07:00 am
amrn
Amarin Reports Third Quarter 2025 Financial Results
Medium
Report
Amarin Reports Third Quarter 2025 Financial Results
10/27
08:00 am
amrn
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
Medium
Report
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
10/22
06:56 am
amrn
Amarin (NASDAQ:AMRN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Amarin (NASDAQ:AMRN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/15
08:00 am
amrn
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
Low
Report
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
10/14
09:03 am
amrn
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Globe and Mail, The (Toronto, Canada)]
Low
Report
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Globe and Mail, The (Toronto, Canada)]
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2025
07:00 am
AMRN
amarin corporation plc - american depositary shares
BEAT
Report
-14.8%
amarin corporation plc - american depositary shares
7/30/2025
07:00 am
AMRN
amarin corporation plc - american depositary shares
BEAT
Report
3.2%
amarin corporation plc - american depositary shares
3/12/2025
07:00 am
AMRN
amarin corporation plc - american depositary shares
BEAT
Report
-12.8%
amarin corporation plc - american depositary shares
3/12/2025
07:00 am
AMRN
amarin corporation plc - american depositary shares
BEAT
Report
-9.0%
amarin corporation plc - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/31
04:30 pm
amrn
Form 3 AMARIN CORP PLC\UK For: Oct 17 Filed by: Keenan David Paul
Medium
Report
Form 3 AMARIN CORP PLC\UK For: Oct 17 Filed by: Keenan David Paul
10/29
07:06 am
amrn
Form 10-Q AMARIN CORP PLC\UK For: Sep 30
Medium
Report
Form 10-Q AMARIN CORP PLC\UK For: Sep 30
10/29
07:05 am
amrn
Form 8-K AMARIN CORP PLC\UK For: Oct 29
Medium
Report
Form 8-K AMARIN CORP PLC\UK For: Oct 29
10/22
05:00 pm
amrn
Form 8-K AMARIN CORP PLC\UK For: Oct 17
Low
Report
Form 8-K AMARIN CORP PLC\UK For: Oct 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/1
Amarin Co. plc (NASDAQ: AMRN) had its price target lowered by analysts at Citigroup Inc from $24.00 to $6.00. They now have a "buy" rating on the stock.
25.4%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
TOP News Decliners
3/15
Amarin Takes Proactive Steps to Support Public Health Priorities
-17.6%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: